Volume 31, No 12, Dec 2021

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 31 Issue 12, December 2021: 1228-1229

RESEARCH HIGHLIGHTS

Leveraging immunochemotherapy for treating pancreatic cancer

Anushka Dongre¹ , Robert A. Weinberg^1,2,3,*

¹Whitehead Institute for Biomedical Research, Cambridge, MA, USA
²Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA
³MIT Ludwig Center for Molecular Oncology, Cambridge, MA, USA
Correspondence: Robert A. Weinberg(weinberg@wi.mit.edu)

The refractory response of pancreatic ductal adenocarcinoma (PDAC) to multiple treatment regimens can be attributed to the presence of a desmoplastic stroma together with an immunosuppressive tumor microenvironment. In a recent study published in Cell , Koikawa et al. demonstrate that targeting the proline isomerase, Pin1, potentiates the efficacy of immunochemotherapy and enhances the susceptibility of highly resistant PDAC to the anti-tumor immune response.

https://doi.org/10.1038/s41422-021-00574-x

FULL TEXT | PDF

Browse 747